Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Xiang Fang

Xiang Fang

PhD student
Developing antibody-drug conjugates and CAR T-cells for osteosarcoma patients

 

During my master's, I worked on the signaling pathways underlying osteosarcoma, and in 2022 I obtained my master's degree in Surgery (M.Med.). In November 2023, I joined the Janda group to start my PhD. My project is about developing new therapies for osteosarcoma based on nanobodies, such as antibody-drug conjugate (ADC)  and chimeric antigen receptor (CAR) T-cells. An ADC is created by attaching small toxins to an antibody or antibody fragment, which combines specific targeting and high drug activity. As a new targeted therapeutic drug, ADC has shown excellent efficacy and potential in the field of cancer therapy. Another way to treat cancer is with CAR T-cell immunotherapy. For this therapy, T-cells from the patient are genetically engineered to express a receptor that targets a specific protein, also referred to as antigen. The new receptor binds to an antigen that is (almost) exclusively present on the surface of cancer cells. Upon binding of the antigen, the T-cells can induce tumor cell killing. With these studies, we aim to improve treatment outcomes for children with osteosarcoma.